Fumio Takei, Phd
Distinguished Scientist, Terry Fox Laboratory and
immunology
STEMCELLTechnologies
Chad
Biography
Dr. Takei is a Distinguished Scientist at the Terry Fox Laboratory within the BC Cancer Research Center in Vancouver, Canada. He received his PhD from the University of British Columbia (UBC) and completed postdoctoral training in Cambridge, England. He then returned to UBC to lead his own laboratory. Dr. Takei has over 25 years of experience in immunological research. From 1990 to 2010, his research focused on NK cells, including their surface receptors, molecular regulation and development. In 2010, he discovered a unique lymphocyte population in mouse lungs and this unique finding was later published in 20121. Today, this population of cells is termed group 2 innate lymphoid cells (ILC2s). Since then, Dr. Takei became known as one of the leading experts in ILC2 biology, and the research focus in his lab shifted towards the regulation and function of this newly discovered cell type. Dr. Takei is a Distinguished Scientist at the Terry Fox Laboratory within the BC Cancer Research Center in Vancouver, Canada. He received his PhD from the University of British Columbia (UBC) and completed postdoctoral training in Cambridge, England. He then returned to UBC to lead his own laboratory. Dr. Takei has over 25 years of experience in immunological research. From 1990 to 2010, his research focused on NK cells, including their surface receptors, molecular regulation and development. In 2010, he discovered a unique lymphocyte population in mouse lungs and this unique finding was later published in 20121. Today, this population of cells is termed group 2 innate lymphoid cells (ILC2s). Since then, Dr. Takei became known as one of the leading experts in ILC2 biology, and the research focus in his lab shifted towards the regulation and function of this newly discovered cell type.
Research Interest
Role of Group 2 Innate Lymphoid Cells (ILC2s) in Allergic Inflammation Identification and Isolation of ILC2s